ExpertPerspectives: Recent Advances and Optimal Management of Erythropoietic Protoporphyria and X-linked Protoporphyria

To participate in this activity, please:

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are cutaneous porphyria responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances, including new classes of medications, continue to be made. In this educational activity, Karl Anderson, MD, discusses preventive and therapeutic options for patients with EPP and XLP, as well as the safety and efficacy of emerging treatments.

Course Credit:

0.5 AMA PRA Category 1 CreditsTM


Opens: 2022-08-17
Closes: 2023-08-17

Target Audience:

This activity is intended for a national audience of hematologists, hepatologists, gastroenterologists, medical geneticists, dermatologists, advanced care practitioners, primary care physicians, and other healthcare providers who may be involved in diagnosis and treatment of patients with EPP and XLP.

This educational activity is supported by an educational grant from Mitsubishi Tanabe Pharma Development America, Inc.

    Presenting Faculty

  • Karl E. Anderson, MD

    Galveston Porphyria Laboratory & Center
    Professor, Departments of Internal Medicine (Division of Gastroenterology & Hepatology) and Preventive Medicine and Population Health
    Director, Clinical Science Graduate Program
    Director, Porphyria Laboratory & Center
    University of Texas Medical Branch/UTMB Health
    Galveston, Texas